Immediate Impact
1 from Science/Nature 64 standout
Citing Papers
Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
2025 Standout
Works of Jing Ke being referenced
Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jing Ke | 363 | 295 | 126 | 169 | 56 | 800 | |
| Jiaqing Shao | 243 | 251 | 110 | 165 | 56 | 764 | |
| Weihui Yu | 391 | 264 | 101 | 221 | 40 | 931 | |
| Motoshi Ouchi | 232 | 256 | 105 | 175 | 56 | 813 | |
| Richard Reneland | 348 | 200 | 209 | 154 | 28 | 907 | |
| Paola Simeone | 232 | 220 | 175 | 118 | 35 | 780 | |
| Seung Ho Hong | 232 | 199 | 200 | 236 | 40 | 836 | |
| W Waldhäusl | 313 | 486 | 83 | 196 | 48 | 956 | |
| Yukihiro Nagai | 224 | 197 | 67 | 210 | 49 | 783 | |
| Kenji Mizuno | 302 | 227 | 280 | 243 | 82 | 858 | |
| Atsushi Yamamoto | 341 | 219 | 184 | 175 | 73 | 917 |
All Works
Login with ORCID to disown or claim papers
Loading papers...